{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:17:04Z","timestamp":1784305024742,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02735-z","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T08:35:23Z","timestamp":1745483723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["CAR T-cell therapy in renal cell carcinoma: opportunities, challenges, and new strategies to overcome"],"prefix":"10.1007","volume":"42","author":[{"given":"Mahan","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houshang","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantea","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"1","key":"2735_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4103\/1319-2442.391003","volume":"34","author":"VA Patel","year":"2023","unstructured":"Patel VA, Popat NP. Essentials of Computed Tomography Imaging of Hematuria. Saudi J Kidn Dis Transp. 2023;34(1):61\u201379.","journal-title":"Saudi J Kidn Dis Transp"},{"issue":"7","key":"2735_CR2","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3390\/ijms21072532","volume":"21","author":"A Deleuze","year":"2020","unstructured":"Deleuze A, Saout J, Dugay F, Peyronnet B, Mathieu R, Verhoest G, et al. Immunotherapy in renal cell carcinoma: the future is now. Int J Mol Sci. 2020;21(7):2532.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2735_CR3","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","volume":"21","author":"AK Singh","year":"2020","unstructured":"Singh AK, McGuirk JP. CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol. 2020;21(3):e168\u201378.","journal-title":"Lancet Oncol"},{"key":"2735_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.omto.2021.03.003","volume":"20","author":"R Sakemura","year":"2021","unstructured":"Sakemura R, Can I, Siegler EL, Kenderian SS. In vivo CART cell imaging: paving the way for success in CART cell therapy. Mol Therap-Oncolyt. 2021;20:625\u201333.","journal-title":"Mol Therap-Oncolyt"},{"issue":"3","key":"2735_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79.","journal-title":"World J Oncol"},{"issue":"7","key":"2735_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41585-022-00592-3","volume":"19","author":"A Ingels","year":"2022","unstructured":"Ingels A, Campi R, Capitanio U, Amparore D, Bertolo R, Carbonara U, et al. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol. 2022;19(7):391\u2013418.","journal-title":"Nat Rev Urol"},{"key":"2735_CR7","doi-asserted-by":"publisher","first-page":"1133832","DOI":"10.3389\/fonc.2023.1133832","volume":"13","author":"J Yang","year":"2023","unstructured":"Yang J, Wang K, Yang Z. Treatment strategies for clear cell renal cell carcinoma: past, present and future. Front Oncol. 2023;13:1133832.","journal-title":"Front Oncol"},{"issue":"1","key":"2735_CR8","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/TP.0000000000003762","volume":"106","author":"DO Dahle","year":"2022","unstructured":"Dahle DO, Skauby M, Langberg CW, Brabrand K, Wessel N, Midtvedt K. Renal cell carcinoma and kidney transplantation: a narrative review. Transplantation. 2022;106(1):e52-63.","journal-title":"Transplantation"},{"issue":"3","key":"2735_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/cancers15030665","volume":"15","author":"AM Kase","year":"2023","unstructured":"Kase AM, George DJ, Ramalingam S. Clear cell renal cell carcinoma: from biology to treatment. Cancers. 2023;15(3):665.","journal-title":"Cancers"},{"issue":"1","key":"2735_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12951-022-01761-7","volume":"21","author":"R Wu","year":"2023","unstructured":"Wu R, Wang K, Gai Y, Li M, Wang J, Wang C, et al. Nanomedicine for renal cell carcinoma: imaging, treatment and beyond. J Nanobiotechnol. 2023;21(1):3.","journal-title":"J Nanobiotechnol"},{"issue":"21","key":"2735_CR11","doi-asserted-by":"publisher","first-page":"15688","DOI":"10.3390\/ijms242115688","volume":"24","author":"AC Uscanga-Palomeque","year":"2023","unstructured":"Uscanga-Palomeque AC, Ch\u00e1vez-Escamilla AK, Alvizo-B\u00e1ez CA, Saavedra-Alonso S, Terrazas-Armend\u00e1riz LD, Tamez-Guerra RS, et al. CAR-T cell therapy: from the shop to Cancer therapy. Int J Mol Sci. 2023;24(21):15688.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2735_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12894-024-01401-2","volume":"24","author":"E Ar\u0131","year":"2024","unstructured":"Ar\u0131 E, K\u00f6seo\u011flu H, Ero\u011flu T. Predictive value of SIRI and SII for metastases in RCC: a prospective clinical study. BMC Urol. 2024;24(1):14.","journal-title":"BMC Urol"},{"issue":"2","key":"2735_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/ijms22020843","volume":"22","author":"J Korbecki","year":"2021","unstructured":"Korbecki J, Kojder K, Kapczuk P, Kupnicka P, Gawro\u0144ska-Szklarz B, Gutowska I, et al. The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors\u2014a review of literature. Int J Mol Sci. 2021;22(2):843.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2735_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.21037\/tau.2020.01.21","volume":"9","author":"Y Lu","year":"2020","unstructured":"Lu Y, Song Y, Xu Y, Ou N, Liang Z, Hu R, et al. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients. Transl Androl Urol. 2020;9(2):367.","journal-title":"Transl Androl Urol"},{"issue":"1","key":"2735_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/cancers13010134","volume":"13","author":"A Mpakali","year":"2021","unstructured":"Mpakali A, Stratikos E. The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. Cancers. 2021;13(1):134.","journal-title":"Cancers"},{"issue":"7","key":"2735_CR16","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.3390\/ijms24076710","volume":"24","author":"C Moeckel","year":"2023","unstructured":"Moeckel C, Bakhl K, Georgakopoulos-Soares I, Zaravinos A. The efficacy of tumor mutation burden as a biomarker of response to immune checkpoint inhibitors. Int J Mol Sci. 2023;24(7):6710.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2735_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-024-02047-2","volume":"23","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Wang J, Wang J, Yang S, Wang R, Zhang G, et al. Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond. Mol Cancer. 2024;23(1):131.","journal-title":"Mol Cancer"},{"issue":"7","key":"2735_CR18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","volume":"17","author":"P Mittal","year":"2020","unstructured":"Mittal P, Roberts CW. The SWI\/SNF complex in cancer\u2014biology, biomarkers and therapy. Nat Rev Clin Oncol. 2020;17(7):435\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"2735_CR19","doi-asserted-by":"publisher","first-page":"629722","DOI":"10.3389\/fimmu.2020.629722","volume":"11","author":"SI Kim","year":"2021","unstructured":"Kim SI, Cassella CR, Byrne KT. Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes. Front Immunol. 2021;11:629722.","journal-title":"Front Immunol"},{"key":"2735_CR20","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202358262","author":"P Hunter","year":"2023","unstructured":"Hunter P. The four fronts of immunotherapy. EMBO Rep. 2023. https:\/\/doi.org\/10.15252\/embr.202358262.","journal-title":"EMBO Rep"},{"issue":"7","key":"2735_CR21","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1080\/21645515.2020.1870846","volume":"17","author":"Y Xu","year":"2021","unstructured":"Xu Y, Miller CP, Warren EH, Tykodi SS. Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma. Hum Vaccin Immunother. 2021;17(7):1882\u201396.","journal-title":"Hum Vaccin Immunother"},{"key":"2735_CR22","unstructured":"Righi M. Enhancement of Adoptive Cell Therapies via novel engineered Chimeric Cytokine Receptor: UCL (University College London); 2021."},{"issue":"6","key":"2735_CR23","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.21873\/anticanres.16431","volume":"43","author":"M Kankuri-Tammilehto","year":"2023","unstructured":"Kankuri-Tammilehto M, Perasto L, Pyrhonen S, Salminen E. Long-term outcome with prolonged use of interferon-alpha administered intermittently for metastatic renal cell carcinoma: a phase II study. Anticancer Res. 2023;43(6):2645\u201357.","journal-title":"Anticancer Res"},{"issue":"2","key":"2735_CR24","doi-asserted-by":"publisher","first-page":"e20230903","DOI":"10.1084\/jem.20230903","volume":"221","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med. 2024;221(2):e20230903.","journal-title":"J Exp Med"},{"issue":"11","key":"2735_CR25","doi-asserted-by":"publisher","first-page":"e3550","DOI":"10.1002\/jgm.3550","volume":"25","author":"B Cesur-Erg\u00fcn","year":"2023","unstructured":"Cesur-Erg\u00fcn B, Demir-Dora D. Gene therapy in cancer. J Gene Med. 2023;25(11):e3550.","journal-title":"J Gene Med"},{"key":"2735_CR26","doi-asserted-by":"publisher","first-page":"1526137","DOI":"10.3389\/fimmu.2025.1526137","volume":"16","author":"Z Song","year":"2025","unstructured":"Song Z, Tao Y, You J. The potential applications of peptide-loading complex in cancer treatment. Front Immunol. 2025;16:1526137.","journal-title":"Front Immunol"},{"issue":"12","key":"2735_CR27","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1097\/MS9.0000000000001375","volume":"85","author":"MS Asghar","year":"2023","unstructured":"Asghar MS, Shah SMI, Rani A, Kazmi S, Savul IS, Ukrani J, et al. Toxicities of CAR T-cell therapy: a review of current literature. Ann Med Surg. 2023;85(12):6013\u201320.","journal-title":"Ann Med Surg"},{"key":"2735_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13:1\u201319.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2735_CR29","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","volume":"12","author":"RM Young","year":"2022","unstructured":"Young RM, Engel NW, Uslu U, Wellhausen N, June CH. Next-generation CAR T-cell therapies. Cancer Discov. 2022;12(7):1625\u201333.","journal-title":"Cancer Discov"},{"key":"2735_CR30","doi-asserted-by":"publisher","first-page":"1121030","DOI":"10.3389\/fimmu.2023.1121030","volume":"14","author":"M Hiltensperger","year":"2023","unstructured":"Hiltensperger M, Krackhardt AM. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Front Immunol. 2023;14:1121030.","journal-title":"Front Immunol"},{"key":"2735_CR31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178915","author":"P Barata","year":"2024","unstructured":"Barata P, Gulati S, Elliott A, Hammers HJ, Burgess E, Gartrell BA, et al. Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI178915.","journal-title":"J Clin Invest"},{"issue":"14","key":"2735_CR32","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","volume":"82","author":"SH Panowski","year":"2022","unstructured":"Panowski SH, Srinivasan S, Tan N, Tacheva-Grigorova SK, Smith B, Mak YS, et al. Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma. Can Res. 2022;82(14):2610\u201324.","journal-title":"Can Res"},{"issue":"6","key":"2735_CR33","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41417-021-00359-9","volume":"29","author":"R Rezaei","year":"2022","unstructured":"Rezaei R, Esmaeili Gouvarchin Ghaleh H, Farzanehpour M, Dorostkar R, Ranjbar R, Bolandian M, et al. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy. Cancer Gene Ther. 2022;29(6):647\u201360.","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"2735_CR34","volume":"16","author":"SK Ghorai","year":"2024","unstructured":"Ghorai SK, Pearson AN. Current strategies to improve chimeric antigen receptor T (CAR-T) cell persistence. Cureus. 2024;16(7): e65291.","journal-title":"Cureus"},{"key":"2735_CR35","doi-asserted-by":"crossref","unstructured":"Pal SK, Tran B, Haanen JB, Hurwitz ME, Sacher A, Tannir NM, et al. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discovery. 2024: OF1-OF14.","DOI":"10.1158\/2159-8290.26134420"},{"issue":"1","key":"2735_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/CJI.0000000000000301","volume":"43","author":"H Li","year":"2020","unstructured":"Li H, Ding J, Lu M, Liu H, Miao Y, Li L, et al. CAIX-specific CAR-T cells and sunitinib show synergistic effects against metastatic renal cancer models. J Immunother. 2020;43(1):16\u201328.","journal-title":"J Immunother"},{"key":"2735_CR37","doi-asserted-by":"publisher","first-page":"673276","DOI":"10.3389\/fonc.2021.673276","volume":"11","author":"F Marofi","year":"2021","unstructured":"Marofi F, Al-Awad AS, Sulaiman Rahman H, Markov A, Abdelbasset WK, Ivanovna Enina Y, et al. RETRACTED: CAR-NK Cell: a new paradigm in tumor immunotherapy. Front Oncol. 2021;11:673276.","journal-title":"Front Oncol"},{"issue":"1","key":"2735_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W, Liu Y, He Z, Li L, Liu S, Jiang M, et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discovery. 2024;10(1):40.","journal-title":"Cell Death Discovery"},{"issue":"1","key":"2735_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12(1):14.","journal-title":"Exp Hematol Oncol"},{"key":"2735_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110311","author":"Y Yang","year":"2024","unstructured":"Yang Y, Luo K, Xu G. Acute kidney injury following chimeric antigen receptor T-cell therapy: epidemiology mechanism and prognosis. Clin Immunol. 2024. https:\/\/doi.org\/10.1016\/j.clim.2024.110311.","journal-title":"Clin Immunol"},{"issue":"1","key":"2735_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","volume":"76","author":"S Gupta","year":"2020","unstructured":"Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O\u2019Donnell EK, Jacobson CA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am J Kidney Dis. 2020;76(1):63\u201371.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2735_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"2735_CR43","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013044","author":"F Perna","year":"2024","unstructured":"Perna F, Parekh S, Diorio C, Smith M, Subklewe M, Mehta R, et al. CAR T cell toxicities: bedside to bench-how novel toxicities inform laboratory investigations. Blood Adv. 2024. https:\/\/doi.org\/10.1182\/bloodadvances.2024013044.","journal-title":"Blood Adv"},{"issue":"7","key":"2735_CR44","first-page":"418","volume":"29","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Jain MD, Smith EL. Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma. Trans Cell Ther. 2023;29(7):418\u201328.","journal-title":"Trans Cell Ther"},{"issue":"1","key":"2735_CR45","doi-asserted-by":"publisher","first-page":"e2016605118","DOI":"10.1073\/pnas.2016605118","volume":"118","author":"AA Svoronos","year":"2021","unstructured":"Svoronos AA, Engelman DM. Pharmacokinetic modeling reveals parameters that govern tumor targeting and delivery by a pH-Low Insertion Peptide (pHLIP). Proc Natl Acad Sci. 2021;118(1):e2016605118.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"2735_CR46","doi-asserted-by":"publisher","first-page":"2000845","DOI":"10.1002\/adhm.202000845","volume":"10","author":"S Wang","year":"2021","unstructured":"Wang S, Sun Z, Hou Y. Engineering nanoparticles toward the modulation of emerging cancer immunotherapy. Adv Healthcare Mater. 2021;10(5):2000845.","journal-title":"Adv Healthcare Mater"},{"key":"2735_CR47","doi-asserted-by":"publisher","first-page":"106742","DOI":"10.1016\/j.phrs.2023.106742","volume":"190","author":"A Zinzi","year":"2023","unstructured":"Zinzi A, Gaio M, Liguori V, Cagnotta C, Paolino D, Paolisso G, et al. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data. Pharmacol Res. 2023;190:106742.","journal-title":"Pharmacol Res"},{"key":"2735_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.565857","volume":"10","author":"G Schepisi","year":"2020","unstructured":"Schepisi G, Conteduca V, Casadei C, Gurioli G, Rossi L, Gall\u00e0 V, et al. Potential application of chimeric antigen receptor (CAR)-T cell therapy in renal cell tumors. Front Oncol. 2020;10: 565857.","journal-title":"Front Oncol"},{"issue":"18","key":"2735_CR49","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3390\/cells13181596","volume":"13","author":"E Bartoszewska","year":"2024","unstructured":"Bartoszewska E, Tota M, Kisielewska M, Skowron I, Sebastianka K, Stefaniak O, et al. Overcoming antigen escape and T-cell exhaustion in CAR-T therapy for leukemia. Cells. 2024;13(18):1596.","journal-title":"Cells"},{"issue":"4","key":"2735_CR50","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/cancers14040978","volume":"14","author":"LG White","year":"2022","unstructured":"White LG, Goy HE, Rose AJ, McLellan AD. Controlling cell trafficking: addressing failures in CAR T and NK cell therapy of solid tumours. Cancers. 2022;14(4):978.","journal-title":"Cancers"},{"issue":"1","key":"2735_CR51","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, An L, Huang R, Xiong J, Yang H, Wang X, et al. Strategies to enhance CAR-T persistence. Biomark Res. 2022;10(1):86.","journal-title":"Biomark Res"},{"issue":"37","key":"2735_CR52","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.1039\/D2TB00592A","volume":"10","author":"S Balagopal","year":"2022","unstructured":"Balagopal S, Sasaki K, Kaur P, Nikolaidi M, Ishihara J. Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy. J Mater Chem B. 2022;10(37):7491\u2013511.","journal-title":"J Mater Chem B"},{"issue":"23","key":"2735_CR53","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-21-1559","volume":"27","author":"J Lemoine","year":"2021","unstructured":"Lemoine J, Ruella M, Houot R. Overcoming intrinsic resistance of cancer cells to CAR T-cell killing. Clin Cancer Res. 2021;27(23):6298\u2013306.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2735_CR54","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13578-023-01073-9","volume":"13","author":"B Wang","year":"2023","unstructured":"Wang B, Han Y, Zhang Y, Zhao Q, Wang H, Wei J, et al. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms. Cell Biosci. 2023;13(1):120.","journal-title":"Cell Biosci"},{"issue":"1","key":"2735_CR55","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-chembioeng-092120-092914","volume":"13","author":"TA Gao","year":"2022","unstructured":"Gao TA, Chen YY. Engineering next-generation CAR-T cells: overcoming tumor hypoxia and metabolism. Annu Rev Chem Biomol Eng. 2022;13(1):193\u2013216.","journal-title":"Annu Rev Chem Biomol Eng"},{"issue":"1","key":"2735_CR56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","volume":"20","author":"T Kouro","year":"2022","unstructured":"Kouro T, Himuro H, Sasada T. Exhaustion of CAR T cells: potential causes and solutions. J Transl Med. 2022;20(1):239.","journal-title":"J Transl Med"},{"issue":"5","key":"2735_CR57","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/cancers12051075","volume":"12","author":"S Kailayangiri","year":"2020","unstructured":"Kailayangiri S, Altvater B, Wiebel M, Jamitzky S, Rossig C. Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers. Cancers. 2020;12(5):1075.","journal-title":"Cancers"},{"key":"2735_CR58","doi-asserted-by":"publisher","first-page":"204993612110367","DOI":"10.1177\/20499361211036773","volume":"8","author":"AG Stewart","year":"2021","unstructured":"Stewart AG, Henden AS. Infectious complications of CAR T-cell therapy: a clinical update. Therap Adv Infect Dis. 2021;8:20499361211036772.","journal-title":"Therap Adv Infect Dis"},{"issue":"3","key":"2735_CR59","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","volume":"21","author":"C Roddie","year":"2019","unstructured":"Roddie C, O\u2019Reilly M, Pinto JDA, Vispute K, Lowdell M. Manufacturing chimeric antigen receptor T cells: issues and challenges. Cytotherapy. 2019;21(3):327\u201340.","journal-title":"Cytotherapy"},{"issue":"4","key":"2735_CR60","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/cancers15041052","volume":"15","author":"S Pagotto","year":"2023","unstructured":"Pagotto S, Simeone P, Brocco D, Catitti G, De Bellis D, Vespa S, et al. CAR-T-derived extracellular vesicles: a promising development of CAR-T anti-tumor therapy. Cancers. 2023;15(4):1052.","journal-title":"Cancers"},{"issue":"4","key":"2735_CR61","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.3390\/ijms22042158","volume":"22","author":"EE Burkova","year":"2021","unstructured":"Burkova EE, Sedykh SE, Nevinsky GA. Human placenta exosomes: biogenesis, isolation, composition, and prospects for use in diagnostics. Int J Mol Sci. 2021;22(4):2158.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2735_CR62","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10561-023-10073-5","volume":"25","author":"A Karimian","year":"2024","unstructured":"Karimian A, Khoshnazar SM, Kazemi T, Asadi A, Abdolmaleki A. Role of secretomes in cell-free therapeutic strategies in regenerative medicine. Cell Tiss Bank. 2024;25(2):411\u201326.","journal-title":"Cell Tiss Bank"},{"key":"2735_CR63","doi-asserted-by":"crossref","unstructured":"Tian J, Han Z, Song D, Peng Y, Xiong M, Chen Z, et al. Engineered exosome for drug delivery: recent development and clinical applications. International Journal of Nanomedicine. 2023:7923\u201340.","DOI":"10.2147\/IJN.S444582"},{"issue":"1","key":"2735_CR64","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","volume":"11","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Taremi S, Heidari M, Esmaeilzadeh A. The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomarker Res. 2023;11(1):103.","journal-title":"Biomarker Res"},{"key":"2735_CR65","doi-asserted-by":"crossref","unstructured":"Blud D, Rubio-Reyes P, Perret R, Weinkove R, editors. Tuning CAR T-cell therapies for efficacy and reduced toxicity. Seminars in hematology; 2024: Elsevier.","DOI":"10.1053\/j.seminhematol.2024.07.003"},{"issue":"8","key":"2735_CR66","first-page":"999","volume":"23","author":"S Changizi-Ashtiyani","year":"2020","unstructured":"Changizi-Ashtiyani S, Hafazeh L, Ghasemi F, Najafi H, Babaei S, JalallyMashayekhi F, et al. The effect of adipose-derived mesenchymal stem cells on renal function and histopathology in a rat model of ischemia-reperfusion induced acute kidney injury. Iran J Basic Med Sci. 2020;23(8):999.","journal-title":"Iran J Basic Med Sci"},{"issue":"6","key":"2735_CR67","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41423-020-0470-3","volume":"17","author":"L Wu","year":"2020","unstructured":"Wu L, Wei Q, Brzostek J, Gascoigne NR. Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells. Cell Mol Immunol. 2020;17(6):600\u201312.","journal-title":"Cell Mol Immunol"},{"key":"2735_CR68","doi-asserted-by":"crossref","unstructured":"Srour SA, Chahoud J, Drakaki A, Curti BD, Pal S, Tang L, et al. 322 ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): updated safety and efficacy from the phase 1 TRAVERSE multicenter study. BMJ Specialist Journals; 2024.","DOI":"10.1136\/jitc-2024-SITC2024.0322"},{"issue":"3","key":"2735_CR69","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/KCA-220001","volume":"6","author":"Y Lyou","year":"2022","unstructured":"Lyou Y, Dorff TB. Chimeric antigen receptor (CAR) T-cell treatment in renal cell carcinoma: current clinical trials and future directions. Kidney Cancer. 2022;6(3):159\u201368.","journal-title":"Kidney Cancer"},{"issue":"5","key":"2735_CR70","doi-asserted-by":"publisher","first-page":"486","DOI":"10.4111\/icu.20220103","volume":"63","author":"TJ Kim","year":"2022","unstructured":"Kim TJ, Lee YH, Koo KC. Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: a comprehensive review. Invest Clin Urol. 2022;63(5):486.","journal-title":"Invest Clin Urol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02735-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T15:02:23Z","timestamp":1748703743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02735-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["2735"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02735-z","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by research deputy of Kermanshah University of Medical Sciences, Kermanshah, Iran (Ethics approval ID: IR.KUMS.REC.1401.253).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"179"}}